ArticleFrontiers in immunology2025
The timing of concurrent intrathecal chemotherapy during blinatumomab infusion influences neurotoxicity in pediatric acute lymphoblastic leukemia.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To assess the safety profile of administering intrathecal (IT) chemotherapy concurrently with blinatumomab in pediatric patients with acute lymphoblastic leukemia (ALL). Methods: This retrospective analysis included 93 pediatric ALL patients treated between February 2021 and May 2025 who received blinatumomab. Results: Of the 93 enrolled patients (median [Q1, Q3] age, 6 [4, 12] years), 42 (45%) were given IT chemotherapy concurrently, while the remaining 51 (55%) served as controls. Neurotoxic events occurred in eight patients (8.8%) overall, with no statistically significant difference between the concurrent IT and control groups (12% vs. 6%, p = 0.461). However, receiving IT chemotherapy on Day 1 of blinatumomab was strongly associated with neurotoxicity (OR = 15.6; 95% CI: 2.96-87.8; p = 0.001). Additional univariate predictors included CD4+ T-cell count (OR = 0.03; 95% CI: 0.00-0.50; p = 0.045), serum albumin (OR = 1.17; 95% CI: 1.02-1.39; p = 0.042), and bone marrow blast percentage (OR = 1.05; 95% CI: 1.01-1.09; p = 0.017). Multivariate analysis identified Day 1 concurrent IT administration as an independent risk factor (OR = 12.5; 95% CI: 1.45-131; p = 0.023). Conclusions: Initiating IT chemotherapy on the same day as blinatumomab infusion significantly increases the risk of neurotoxicity in pediatric ALL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.